Integra LifeSciences Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Integra LifeSciences (IART) Tops Q2 EPS by 7c, Revenues Beat; Raises FY19 EPS Guidance, Affirms FY19 Revenue Outlook
July 24, 2019 5:50 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.73, $0.07 better than the analyst estimate of $0.66. Revenue for the quarter came in at $383.6 million versus the consensus estimate of $373.29 million.
Second Quarter 2019 Highlights
Reported revenues were $383.6 million, an increase of 4.8% compared to the second quarter of 2018, and organic revenues increased 6.6% over the prior-year quarter; - Reported revenues in the Codman Specialty Surgical segment increased 4.1% compared to the second quarter of 2018; - Reported revenues in the Orthopedics and Tissue Technologies segment increased 6.1% compared to the second quarter of 2018; - Foreign currency... More
